FibroGen (NASDAQ:FGEN) Receives News Impact Rating of 0.20

Press coverage about FibroGen (NASDAQ:FGEN) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. FibroGen earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 43.8149855791893 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Shares of FibroGen (NASDAQ:FGEN) traded down $1.70 during trading on Tuesday, hitting $47.80. The company had a trading volume of 668,323 shares, compared to its average volume of 582,618. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.16. FibroGen has a twelve month low of $21.05 and a twelve month high of $60.15. The firm has a market capitalization of $3,930.00, a PE ratio of -23.55 and a beta of 1.55.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.13). FibroGen had a negative return on equity of 47.36% and a negative net margin of 120.00%. research analysts predict that FibroGen will post -1.75 earnings per share for the current fiscal year.

FGEN has been the subject of a number of research reports. Mizuho restated a “hold” rating and set a $61.00 target price on shares of FibroGen in a research report on Thursday, November 9th. ValuEngine downgraded FibroGen from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, BidaskClub downgraded FibroGen from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $65.67.

In related news, CEO Thomas B. Neff sold 38,636 shares of the company’s stock in a transaction dated Tuesday, October 31st. The stock was sold at an average price of $56.13, for a total transaction of $2,168,638.68. Following the sale, the chief executive officer now owns 3,144,573 shares in the company, valued at $176,504,882.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Thomas B. Neff sold 18,900 shares of the company’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $46.60, for a total value of $880,740.00. Following the sale, the chief executive officer now owns 3,109,555 shares in the company, valued at approximately $144,905,263. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 270,446 shares of company stock worth $12,968,088. Corporate insiders own 13.60% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “FibroGen (NASDAQ:FGEN) Receives News Impact Rating of 0.20” was reported by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://weekherald.com/2018/01/16/fibrogen-fgen-given-news-impact-rating-of-0-20.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply